文献リスト

1) Bone RC. Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome). JAMA. 1992; 268: 3452-5

2) Vincent JL, Moreno R, Takahara J. The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. Intensive Care Med. 1996; 22: 707-10

3) Warren BL, Eid A, Singer P, et al. High-dose antithrombin in severe sepsis. A randomized controlled trial. JAMA. 2001; 286: 1869-78

4) Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human protein C for severe sepsis. N Engl J Med. 2001; 8: 699-709

5) Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003; 290: 238-47

6) Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign Management Guidelines Committee. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004; 32: 858-73

7) Wada H. Disseminated intravascular coagulation. CCA. 2004; 344: 13-21

8) Taylor Jr FB, Toh CH, Hoots WK, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation-On behalf of the Scientific Subcommittee on disseminated intravascular coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Thromb Haemost. 2001; 86: 1327-30

9) 和田英夫. 国内外における播種性血管内凝固症(DIC)の診断基準作成の動きについて. 日本血栓止血学会誌. 2000; 11: 3-15

10) Gando S, Wada H, Asakura H, et al. Evaluation of new Japanese diagnostic criteria for disseminated intravascular coagulation in critically ill patients. Clin Appl Thromb Hemost. 2005; 11: 71-6

11) Gando S, Iba T, Eguchi Y, et al. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group: A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med. 2006; 34: 625-31

12) Aoki N, Matsuda T, Saito H, et al. CTC-111-IM Clinical Research Group. A comparative double-blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. Int J Hematol. 2002; 75: 540-7

13) Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of phase III randomized, double blind, clinical trial. J Thromb Haemost. 2006; [Epub ahead of print]

14) 日本血栓止血学会学術標準化委員会DIC部会. EBMに基づくDICガイドライン作成に向けての調査研究. 血栓止血誌. 2006; 17: 278-360

15) Centre for evidence-Based MedicineのホームページにあるLevels of Evidence and Grades of Recommendations (http:/www.cebm.net/levels_of_evidence.asp) 2001年改訂版

16) 急性膵炎の診療ガイドライン作成出版委員会. In: エビデンスに基づいた急性膵炎の診療ガイドライン. 東京: 金原出版; 2003

17) Kish MA. Infectious Diseases Society of America. Guide to development of practice guidelines. Clin Infect Dis. 2001; 32: 851-4

18) Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood. 2002; 100: 4298-302

19) 青木延雄, 長谷川淳. DIC診断基準の｢診断のための補助的検査成績, 所見｣の項の改訂について, 厚生省特定疾患血液凝固異常症調査研究班, 平成4年度業績報告集. 1988; p. 37-41

20) Wada H, Wakita Y, Nakase T, et al. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Thromb Haemost. 1995; 74: 848-52

21) Kienast J, Juers M, Wiedermann CJ, et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost. 2006; 4: 90-7

22) Feinstein DI. Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapy. Blood. 1982; 60: 284-7

23) Polderman KH, Girbes ARJ. Drug intervention trials in sepsis: divergent results. Lancet. 2004; 363: 1721-3

24) 櫻川信男, 長谷川淳, 真木正博, 他. 汎発性血管内凝固症候群に対する低分子ヘパリン(FR-860)の臨床評価. 臨床医薬. 1991; 8: 423-52

25) 安永幸二郎, 小川鴨也, 森 和夫, 他. DICに対するダナパロイドナトリウム (KB-101)の臨床効果の検討. 薬理と治療. 1995; 23: 363-82

26) Nishiyama T, Matsukawa T, Hanaoka K. Is protease inhibitor a choice for the treatment of pre-or mild disseminated intravascular coagulation？ Crit Care Med. 2000; 28: 1419-22

27) Hsu JT, Chen HM, Chiu DF, et al. Efficacy of gabexate mesilate on disseminated intravascular coagulation as a complication of infection developing after abdominal surgery. J Formos Med Assoc. 2004; 103: 678-84

28) 神前五郎, 上林純一, 平山亮夫, 他. DICに対するFOYの治療効果に関する研究-多施設比較対照試験—. 医学のあゆみ. 1983; 124: 144-54

29) 柴田 昭, 高橋芳右, 青木延雄, 他. 播種性血管内凝固症候群(DIC)に対するFUT-175注(メシル酸ナファモスタット)の治療効果. 臨床と研究. 1988; 65: 921-40

30) Fourrier F, Chopin C, Huart JJ, et al. Double-blind, placebocontrolled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest. 1993; 104: 882-8

31) Baudo F, Caimi TM, de Cataldo F, et al. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med. 1998; 24: 336-42

32) Eisele B, Lamy M, Thijs LG, et al. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med. 1998; 24: 663-72

33) Wiedermann CJ, Hoffmann JN, Juers M, et al. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med. 2006; 34: 285-92

34) Abraham E, Laterre PF, Garg R, et al. Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group: Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med. 2005; 353: 1332-41

35) Vincent JL, Bernard GR, Beale R, et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med. 2005; 33: 2266-77

36) Zenz W, Zoehrer B, Levin M, et al. International Paediatric Meningococcal Thrombolysis Study Group: Use of recombinant tissue plasminogen activator in children with meningococcal purpura fulminans: a retrospective study. Crit Care Med. 2004; 32: 1777-80

37) 厚生労働省. In: 血液製剤の使用指針 (改訂版), 血液製剤の使用にあたって. 厚生労働省, 編. 第3版. 東京: じほう; 2005. p. 24-77

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp